On Apr. 16, 2020, OpGen announced that a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS) had been pre-published in the Journal of Clinical Microbiology.

The study was performed by its newly acquired subsidiaries Ares Genetics and Curetis, and scientists at the Max Perutz Labs (Austria), a joint venture of the University of Vienna and the Medical University of Vienna, and the Mayo Clinic.